New RSV vaccine trial aims to protect vulnerable transplant recipients
NCT ID NCT06593210
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial is testing a non-live, adjuvanted RSV vaccine (Arexvy) in 100 adults who have received a lung or stem cell transplant. The goal is to see if the vaccine is safe and helps their immune system fight RSV, a common virus that can be dangerous for them. Participants will have blood tests before and after vaccination to measure immune response, and will be monitored for side effects, infections, and transplant complications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Arexvy (non-live, adjuvanted RSV vaccine)
What this could lead to
If successful, this could provide a safe and effective RSV vaccine for people with weakened immune systems after transplants, reducing serious infections.
What could go wrong
This is a relatively small, early-phase study (100 participants) and transplant recipients have suppressed immune systems, so the vaccine may not produce a strong immune response or could cause unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Health Network
Toronto, Canada